Gedeon Richter championed the impact of its recent European launches of generic versions of Bayer’s Xarelto (rivaroxaban) and Boehringer Ingelheim’s Pradaxa (dabigatran), as its total Pharma revenues climbed by 10% in constant currencies, and 13% as reported, to HUF844.8bn ($2.30bn) in 2024.
Richter Welcomes Generic Xarelto And Pradaxa Impact As Revenues Climb In 2024
‘Not A Big Bang,’ Firm Admits, But Steady Addition To Operations; Biosimilars Advancing
Gedeon Richter enjoyed a solid 2024 as it capitalized on key generic launches and progressed significantly with proposed biosimilars to both Prolia/Xgeva and Actemra/RoActemra. The Hungarian firm also shed light on its strategy over the next decade in a newly-launched ten-year strategic plan.
